This bill authorizes the Secretary of Defense to establish a program to develop, scale, and transition biotechnology research from military service laboratories into capabilities that strengthen the defense supply chain. The Program can fund applied research and prototyping, upgrade physical and digital laboratory infrastructure, enter into contracts and other transactions with non‑Federal partners, and support workforce development tied to bioindustrial and biomanufacturing efforts.
The statute sets reporting and planning requirements (a 90‑day allocation plan once the Secretary elects to start the Program and annual reports thereafter), requires prioritization of technologies that reduce logistics and foreign reliance (examples include field‑enabled manufacturing, bio‑derived materials, and novel coatings), and sunsets the authority after ten years unless the President certifies continuation for national economic or security reasons. The bill does not itself appropriate funds, but it creates authorities and a reporting structure that would shape DoD investment, procurement pathways, and the domestic bioindustrial base if funded and executed.
At a Glance
What It Does
Permits—but does not force—the Secretary of Defense to stand up a Program that assesses DOD biotech supply chain vulnerabilities, directs service labs to perform applied R&D and rapid prototyping, upgrades facilities, and enters into contracts, grants, cooperative agreements, or other transactions with industry and academia to scale bioindustrial capabilities. The statute requires a 90‑day funding allocation plan after the Secretary elects to commence and mandates annual public reports (with a classified annex option).
Who It Affects
Directly affects military service laboratories, Defense Agencies, prime contractors and nontraditional biomanufacturing companies, academic research partners, and DOD acquisition and logistics offices responsible for transitioning prototypes into programs of record. Indirectly affects regional manufacturing ecosystems where facilities are modernized and workforce training is deployed.
Why It Matters
It formalizes a DoD role in domestic biomanufacturing and gives the Department flexible contracting tools (including other transactions) to accelerate technology transition—potentially changing procurement competition dynamics and where biomanufacturing capacity is built. For compliance and acquisition professionals, it signals new categories of capabilities (bio‑cement, protective coatings, deployable biofabrication) that DOD may prioritize.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a discretionary Defense Biotechnology Supply Chain Resiliency Program. It is not a mandatory spending authorization; instead it gives the Secretary the legal authority to set up and run a program that moves biotechnology innovations out of service labs and toward operational use.
The Program’s stated scope includes bioindustrial chemicals, materials, fuels, and other biologically derived products that can strengthen resilience, sustainability, and responsiveness across the defense supply chain.
Under the Program, the Secretary may order service laboratories to collaborate on applied research and rapid prototyping, and may invest in laboratory modernization—both physical and digital—so prototypes can be scaled. The statute explicitly allows the Department to use multiple transaction types (contracts, cooperative agreements, grants, and other transactions) to partner with commercial firms, research institutions, and academia, and to support workforce development tied to biomanufacturing needs.Implementation is bounded by planning and reporting obligations.
If the Secretary decides to start the Program, DOD must deliver a 90‑day plan for how appropriations would be allocated; annually thereafter DOD must publish an unclassified report (with a classified annex option) describing research activities, partnerships, infrastructure investments, metrics, and obstacles encountered. The statute also requires DOD to prioritize work that mitigates critical supply chain weaknesses—examples called out include field‑capable manufacturing to reduce logistics burdens, novel protective coatings, and biologically derived composites.Finally, the authority expires after ten years unless the President determines continuation is necessary for national economic or security reasons and notifies congressional Armed Services committees.
Because the bill does not appropriate money, its practical impact depends on subsequent congressional funding and on the Secretary’s discretionary choice to commence and resource the Program.
The Five Things You Need to Know
The bill authorizes a discretionary Defense Biotechnology Supply Chain Resiliency Program to develop, scale, and transition bioindustrial R&D—covering biologically derived chemicals, materials, fuels, and other products relevant to defense missions.
The Secretary may use contracts, cooperative agreements, grants, and 'other transactions' to partner with industry, academia, and other federal entities to prototype and pilot biomanufacturing capabilities, enabling nontraditional contractors to participate.
If the Secretary elects to commence the Program, DOD must submit a plan for allocation of appropriations within 90 days; annual unclassified reports (with a classified annex allowed) must follow until the Program ends and must list partnerships, infrastructure investments, performance metrics, and challenges.
The statute directs prioritization of technologies that reduce logistics and foreign dependence—explicit examples include field‑enabled manufacturing (e.g.
bio‑cement), protective coatings, and biologically derived composites—and requires performance metrics tied to transition to programs of record.
Authority to operate the Program sunsets 10 years after enactment unless the President determines continuation is necessary for national economic or security needs and notifies House and Senate Armed Services Committees.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Program scope and permitted activities
These paragraphs define the Program’s purpose and give the Secretary broad, permissive authority to implement it. They enumerate concrete activities: assessing supply chain vulnerabilities; directing service labs to perform applied research, advanced component development, and rapid prototyping; upgrading laboratory infrastructure; and supporting workforce development. For practitioners, the key mechanic is breadth: DOD can act across R&D, facilities, and workforce without being constrained to a single contracting vehicle or institution.
Flexible partnering and workforce provisions
The statute expressly authorizes DOD to enter into contracts, cooperative agreements, grants, or other transactions with federal and non‑federal partners, and to invest in education and training. The inclusion of 'other transactions' matters because it allows DOD to use prototype OT authorities that can speed engagement with nontraditional suppliers and ease IP negotiations, but those authorities also bring different oversight and auditing regimes than traditional procurement contracts.
Prioritization, planning, and reporting requirements
Section 1(a)(3) lists priorities—critical supply chain vulnerabilities, field‑manufacturing, novel materials, and cost efficiencies—and requires consultation with industry and other agencies. Section 1(b) imposes concrete deliverables: a 90‑day funding allocation plan after the Secretary elects to start the Program and annual unclassified reports (with classified annexes permitted) detailing technical objectives, partnerships, infrastructure work, performance against metrics, challenges, and recommendations. These provisions create transparency but do not mandate specific funding levels or timetables for technology transition.
Ten‑year sunset with presidential extension
The authority to operate the Program expires ten years after enactment unless the President certifies continuation for national economic or security reasons and notifies congressional Armed Services committees. That structure makes the Program time‑limited unless executive branch judgment extends it, rather than requiring fresh statutory reauthorization.
This bill is one of many.
Codify tracks hundreds of bills on Defense across all five countries.
Explore Defense in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Military service laboratories and defense research hubs — they gain explicit authority and potential funding to perform applied bioindustrial R&D, to upgrade facilities, and to pilot production models that can be transitioned into operational programs.
- Domestic biomanufacturing companies and startups — the bill opens DoD contracting pathways (including other transactions) and creates a demand signal for commercial-scale bioindustrial production, improving commercial opportunities and access to DOD pilot projects.
- DOD logistics and operational units — by prioritizing field‑enabled manufacturing and materials that reduce logistics burden, the Program aims to deliver operationally relevant capabilities that could shorten supply lines and improve sustainment in austere environments.
- Regional economies and workforce programs — investments in facilities modernization and explicit workforce development support are likely to create skilled jobs and build local industrial capacity where pilot plants or upgraded labs are located.
Who Bears the Cost
- Congress and taxpayers — the bill creates authorities and reporting obligations but contains no appropriations language, so delivering the Program’s ambitions requires new appropriations that will compete with other defense and non‑defense priorities.
- DoD acquisition and program offices — those offices will absorb the burden of integrating prototyped bioproducts into programs of record, developing technical requirements, and meeting the performance metrics the statute mandates.
- Traditional defense contractors — incumbent suppliers may face increased competition from nontraditional biotech firms and startups that enter DOD supply chains via other transactions or cooperative agreements.
- Service laboratories and facility operators — modernization and scaling will require administrative effort, capital investments, and compliance with safety and regulatory standards, potentially stretching lab management resources and requiring cultural shifts toward industrial partnerships.
Key Issues
The Core Tension
The central dilemma is speed versus oversight: Congress is authorizing DoD to rapidly build domestic biomanufacturing capacity to reduce supply‑chain risk and improve operational agility, but accelerating that transition without detailed funding, standard biosafety/security controls, or clear acquisition pathways risks gaps in accountability, export control, and safe commercialization.
The bill trades broad flexibility for limited procedural guardrails. It authorizes a wide range of activities and transaction types but stops short of specifying funding levels, enforceable transition timelines, or explicit biosafety and biosecurity safeguards beyond general consultation requirements.
That combination creates a risk that the Program could accelerate commercialization without standardized protocols for dual‑use risk management, export controls, or coordinated oversight with civilian biosurveillance and public‑health agencies.
Another implementation question concerns procurement and oversight. The use of 'other transactions' and cooperative models accelerates engagement with nontraditional firms but reduces the applicability of normal Federal Acquisition Regulation processes and associated audit and accountability mechanisms.
Likewise, the required performance metrics and transition‑to‑program‑of‑record language create expectations but do not specify who certifies readiness or how IP and cost‑sharing will be handled when prototypes move into acquisition programs. Finally, because the statute makes starting the Program discretionary ('may'), outcomes will depend heavily on internal DOD priorities and available appropriations, producing potential unevenness across services and regions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.